[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521049":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":24,"responsibleParty":37,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":10,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Sanofi","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"The source population for this study is adult participants with severe asthma treated with dupilumab in routine clinical practice in the UK.",[13],"Other: No intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No intervention","Non-interventional study based on secondary use of hospital medical records",[9],[21],{"name":22,"affiliation":5,"role":23},"Clinical Sciences & Operations","STUDY_DIRECTOR",[25],{"facility":26,"status":10,"city":27,"state":10,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Sanofi-Aventis, France","Chilly-Mazarin","91380","France","FR",{"type":32,"coordinates":33},"Point",[34,35],2.31638,48.71489,{"lat":35,"lon":34},{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100521049","an-observational-retrospective-multicentre-medical-record-review-to-describe-the-post-authorisation-early-clinical-experience-of-dupilumab-in-the-treatment-of-adult-severe-asthma-100521049",false,"NCT06064526","An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma","Real-world Experience of Dupilumab for the Treatment of Severe Asthma in the United Kingdom: a Retrospective Study","DUPIAZA","Inclusion Criteria:\n\n• Adult participants (aged ≥18 years at index) with severe asthma, initiated with dupilumab treatment (≥1 dose) between 07\u002F05\u002F2019 (EU licence) and 08\u002F12\u002F2021 • Participants with ≥1 routine asthma clinic visit recorded within 6 months prior to or on the date of dupilumab initiation and ≥1 routine asthma clinic visit recorded between 9 and 16 months post-dupilumab initiation\n\nExclusion Criteria:\n\n• Participants known to have opted out of participation in research • Participants whose medical records are not available for review The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.","ALL","18 Years",{"count":50,"type":51},144,"ACTUAL","OBSERVATIONAL","The purpose of this retrospective medical record review is to describe the real-world clinical effectiveness of dupilumab with patients in the United Kingdom with severe asthma.",[55],"Asthma","COMPLETED","2024-11-13",{"date":59,"type":51},"2024-11-14",{"date":61,"type":51},"2023-04-19",{"date":63,"type":51},"2024-10-15",{"name":5,"class":6},1]